TWI880316B - 貓抗體變異體 - Google Patents

貓抗體變異體 Download PDF

Info

Publication number
TWI880316B
TWI880316B TW112132477A TW112132477A TWI880316B TW I880316 B TWI880316 B TW I880316B TW 112132477 A TW112132477 A TW 112132477A TW 112132477 A TW112132477 A TW 112132477A TW I880316 B TWI880316 B TW I880316B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
igg
amino acid
zts
Prior art date
Application number
TW112132477A
Other languages
English (en)
Chinese (zh)
Other versions
TW202413413A (zh
Inventor
莉莎 柏格倫
亨利 坎普斯
Original Assignee
美商碩騰服務公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商碩騰服務公司 filed Critical 美商碩騰服務公司
Publication of TW202413413A publication Critical patent/TW202413413A/zh
Application granted granted Critical
Publication of TWI880316B publication Critical patent/TWI880316B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112132477A 2020-09-29 2021-09-29 貓抗體變異體 TWI880316B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084693P 2020-09-29 2020-09-29
US63/084,693 2020-09-29

Publications (2)

Publication Number Publication Date
TW202413413A TW202413413A (zh) 2024-04-01
TWI880316B true TWI880316B (zh) 2025-04-11

Family

ID=78599139

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112132477A TWI880316B (zh) 2020-09-29 2021-09-29 貓抗體變異體
TW110136252A TWI814094B (zh) 2020-09-29 2021-09-29 貓抗體變異體
TW114113296A TW202545990A (zh) 2020-09-29 2021-09-29 貓抗體變異體

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110136252A TWI814094B (zh) 2020-09-29 2021-09-29 貓抗體變異體
TW114113296A TW202545990A (zh) 2020-09-29 2021-09-29 貓抗體變異體

Country Status (15)

Country Link
EP (2) EP4221744A1 (https=)
JP (1) JP2023542737A (https=)
KR (1) KR20230091914A (https=)
CN (1) CN116457369A (https=)
AR (1) AR123645A1 (https=)
AU (1) AU2021352395A1 (https=)
CA (1) CA3195049A1 (https=)
CL (2) CL2023000914A1 (https=)
CO (1) CO2023004107A2 (https=)
EC (1) ECSP23030307A (https=)
IL (1) IL301414A (https=)
MX (1) MX2023003694A (https=)
PE (1) PE20240110A1 (https=)
TW (3) TWI880316B (https=)
WO (1) WO2022072446A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123645A1 (es) 2020-09-29 2022-12-28 Zoetis Services Llc Variantes de anticuerpos felinos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
RU2529951C2 (ru) * 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
WO2021212084A1 (en) * 2020-04-17 2021-10-21 Zoetis Services Llc Feline antibody variants
AR123645A1 (es) 2020-09-29 2022-12-28 Zoetis Services Llc Variantes de anticuerpos felinos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use

Also Published As

Publication number Publication date
TW202413413A (zh) 2024-04-01
EP4711383A2 (en) 2026-03-18
TWI814094B (zh) 2023-09-01
JP2023542737A (ja) 2023-10-11
TW202222830A (zh) 2022-06-16
EP4711383A3 (en) 2026-04-29
AU2021352395A1 (en) 2023-04-27
PE20240110A1 (es) 2024-01-22
CO2023004107A2 (es) 2023-04-27
CL2023000914A1 (es) 2023-10-20
CN116457369A (zh) 2023-07-18
IL301414A (en) 2023-05-01
AR123645A1 (es) 2022-12-28
KR20230091914A (ko) 2023-06-23
CA3195049A1 (en) 2022-04-07
MX2023003694A (es) 2023-04-21
EP4221744A1 (en) 2023-08-09
ECSP23030307A (es) 2023-07-31
WO2022072446A1 (en) 2022-04-07
US20230382986A1 (en) 2023-11-30
TW202545990A (zh) 2025-12-01
CL2024000789A1 (es) 2024-07-19

Similar Documents

Publication Publication Date Title
US20250026834A1 (en) Feline antibody variants
TW202204403A (zh) 犬抗體變異體
WO2022133252A1 (en) Mutations in feline antibody constant regions
CN116438196A (zh) 犬抗体变体
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
TWI880316B (zh) 貓抗體變異體
RU2840969C1 (ru) Варианты кошачьих антител
US12612455B2 (en) Feline antibody variants
US12612454B2 (en) Canine antibody variants
RU2858900C2 (ru) Варианты кошачьих антител
RU2847183C1 (ru) Варианты собачьих антител
BR122024007417A2 (pt) Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula